naa a22 4500 51076343X CHVBK 20180411083148.0 cr unu---uuuuu 180411e20130901xx s 000 0 eng 10.1007/s12094-012-1000-2 doi (NATIONALLICENCE)springer-10.1007/s12094-012-1000-2 Radiotherapy alone versus radiochemotherapy in patients with stage IIIA adenocarcinoma (ADC) of the lung [Elektronische Daten] [B. Jeremić, B. Miličić, S. Milisavljević] Purpose: To evaluate the outcome of radiotherapy (RT) versus radiochemotherapy (RT-CHT) in patients with locally advanced (stage III) inoperable adenocarcinoma of the lung. Patients and methods: 146 patients with these characteristics were among 600 patients enrolled into five prospective trials and were treated with either hyperfractionated (Hfx) RT (64.8 and 69.6Gy using 1.2Gy bid) alone (n=33) or with Hfx RT (64.8 and 69.6Gy using 1.2Gy bid and 67.6Gy using 1.3Gy bid) and concurrent carboplatin-etoposide or paclitaxel-carboplatin (n=113). Results: The median times and 5-year overall survival (OS), local progression-free survival (LPFS) and the distant metastasis-free survival (DMFS) rates for all 146 patients were 17, 20 and 20months, respectively, and 15, 26 and 33, respectively. RT-CHT was superior to RT alone in terms of both OS (MST 19 vs. 12months, respectively, 5-year OS 18 vs. 6%, respectively; p=0.003) and LPFS (MTLP 21 vs. 15months, respectively, 5-year LPFS 28 vs. 0%; p=0.06), but not the DMFS (p=0.43). In all 146 patients, the most frequent acute high-grade toxicity was esophageal, bronchopulmonary and hematological (each 12%), while the most frequent late high-grade toxicity was bronchopulmonary (4%) and esophageal (3%). RT-CHT caused significantly more frequent acute high-grade (>3) esophageal (15%), and hematological (15%), while late high-grade toxicity was similar between RT and RT-CHT groups of patients. Conclusion: RT-CHT achieved excellent results (MST 19months, 5-year survival 18%) in this patient population accompanied with low toxicity, comparing favorably to results of other similar studies. Federación de Sociedades Españolas de Oncología (FESEO), 2013 Radiation therapy nationallicence Chemotherapy nationallicence Lung cancer nationallicence Adenocarcinoma nationallicence Jeremić B. Department of Oncology, University Hospital, Kragujevac, Serbia aut Miličić B. Department of Oncology, University Hospital, Kragujevac, Serbia aut Milisavljević S. Department of Oncology, University Hospital, Kragujevac, Serbia aut Clinical and Translational Oncology Springer Milan 15/9(2013-09-01), 747-753 1699-048X 15:9<747 2013 15 12094 https://doi.org/10.1007/s12094-012-1000-2 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-012-1000-2 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Jeremić B. Department of Oncology, University Hospital, Kragujevac, Serbia aut NATIONALLICENCE 700 1- Miličić B. Department of Oncology, University Hospital, Kragujevac, Serbia aut NATIONALLICENCE 700 1- Milisavljević S. Department of Oncology, University Hospital, Kragujevac, Serbia aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/9(2013-09-01), 747-753 1699-048X 15:9<747 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer